The 5 Most Hated Biotechs: Myriad, Sarepta, OncoMed, VIVUS, and MannKind

Not every company in biotech land is loved by investors. In fact, many biotechs top the list of companies with high short interest as a percentage of float.

As of the end of February, Myriad Genetics (NASDAQ: MYGN  ) was the second-most shorted company as a percentage of float. Sarepta Therapeutics  (NASDAQ: SRPT  )  came in at No. 9. OncoMed Pharmaceuticals (NASDAQ: OMED  ) , VIVUS (NASDAQ: VVUS  ) , and MannKind (NASDAQ: MNKD  ) rounded out the top five most-shorted biotechs. 

In the slideshow below, you can see their metrics and reasons why some investors don't like them.

Fear not if your favorite biotech makes the list; Questcor Pharmaceuticals and Ziopharm Oncology, which were in last month's list, fell back in favor -- at least somewhat -- dropping off the top-five list.

A stock pick our chief investment officer loves
While it's true that a highly shorted stock can make you money in a short squeeze, you still have to be confident that other's will buy the stock. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2874881, ~/Articles/ArticleHandler.aspx, 9/2/2014 7:55:08 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement